
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,600 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 January 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 218 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Adaptive Treatment Strategies with Survival Outcomes: An Application to the Treatment of Type 2 Diabetes using a Large Observational Database”, Am J Epidemiol, 2020.
, “Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data”, Schizophr Res, vol. 154, pp. 54-60, 2014.
, “Domperidone for insufficient lactation in England 2002-2015: A drug utilization study with interrupted time series analysis”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 1316-1324, 2018.
, “The Estimation of Gestational Age at Birth in Database Studies”, Epidemiology, vol. 28, pp. 854-862, 2017.
, “Estimation of high-dimensional propensity scores with multiple exposure levels”, Pharmacoepidemiol Drug Saf, 2019.
, “Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research”, Pharmacoepidemiol Drug Saf, 2019.
, “Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink”, Bmj, vol. 355, p. i5340, 2016.
, “Hypertensive Disorders in Pregnancy and the Risk of Subsequent Cardiovascular Disease”, Paediatr Perinat Epidemiol, vol. 31, pp. 412-421, 2017.
, “Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 363, p. k4880, 2018.
, “Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes”, Diabet Med, 2020.
, “A Multicenter Observational Study of Incretin-based Drugs and Heart Failure”, N Engl J Med, vol. 374, pp. 1145-54, 2016.
, “Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example”, Pharmacoepidemiol Drug Saf, 2019.
, “Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer”, Eur Urol, vol. 70, pp. 808-815, 2016.
, “Pioglitazone use and risk of bladder cancer: population based cohort study”, Bmj, vol. 352, p. i1541, 2016.
, “The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding”, Eur J Epidemiol, vol. 27, pp. 77-83, 2012.
, “Postmyocardial Infarction Statin Exposure and the Risk of Stroke with Weighting for Outcome Misclassification”, Epidemiology, vol. 31, pp. 880-888, 2020.
, “Primary Care Prescriptions of Potentially Nephrotoxic Medications in Children with CKD”, Clin J Am Soc Nephrol, 2019.
, “Targeted Maximum Likelihood Estimation for Pharmacoepidemiologic Research”, Epidemiology, vol. 27, pp. 570-7, 2016.
, “The timing of onset of hypertensive disorders in pregnancy and the risk of incident hypertension and cardiovascular disease”, Int J Cardiol, vol. 270, pp. 273-275, 2018.
, ,